Zhao, Y., Wang, Q., Xiao, B., Jia, J., Liu, X., Ma, S., Liu, H., Zhou, T., Yang, Y., Fang, W., Zhang, L., Huang, Y.

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy

14 de August de 2026 by Zhao, Y., Wang, Q., Xiao, B., Jia, J., Liu, X., Ma, S., Liu, H., Zhou, T., Yang, Y., Fang, W., Zhang, L., Huang, Y.

Background
Long-term survival of extensive-stage small-cell lung cancer (ES-SCLC) remains rare, with most patients experiencing disease progression during maintenance therapy. Poly (ADP-ribose) polymerase (PARP) inhibitors have the potential to confer…